With a better understanding of different molecular modeling and cheminformatic approaches, readers can incorporate these techniques into their own drug discovery projects that may involve chemical synthesis and medium- or high-throughput screening. In addition, this book highlights the significance of epigenetic targets to the public health for molecular modelers and chemoinformatians. The goal of this reference is to stimulate ongoing multidisciplinary research and to further improve current computational methodologies and workflows in order to accelerate the discovery and development of epi-drugs and epi-probes.
- Focuses on the discovery of epi-drugs as candidates to be used in therapy including combined therapies- Describes new computational methodologies and screening assays utilizing recent and emerging novel structural data- Highlights the discovery, development and optimization of epi-probes, which are molecular probes that elucidate epigenetic mechanisms- Includes important topics such as computational-guided optimization of epi-hits, virtual screening to identify novel compounds for epigenetic targets, development and mining of epigenetic molecular databases, SAR modeling of screening data and much more
Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.
- Introduction of Epigenetic Targets in Drug Discovery and Current Status of Epi-Drugs and Epi-Probes
- Overview of Computer-Aided Drug Design for Epigenetic Targets
- Structure-Guided Optimization of DNA Methyltransferase Inhibitors
- Discovery and Development of Small Molecules Targeting Epigenetic Enzymes with Computational Methods
- Insilico Optimization of the First DNA-Independent Mechanism-Based Inhibitor of Mammalian DNA Methyltransferase DNMT1
- Structure-Based Modeling of Histone Deacetylases Inhibitors
- Searching Histone Deacetylase Inhibitors under Computational Procedures
- Current Development of Protein Arginine Methyltransferase Inhibitor
- Molecular Design of Compounds Targeting Histone Methyltransferases
- Computational Chemical Biology of Methyllysine Histone Effectors
- Structure-Based Design and Computational Studies of Sirtuin Inhibitors
- Drug Repurposing for Epigenetic Targets Guided by Computational Methods
- Computational Structure-Activity Relationship Studies of Epigenetic Target Inhibitors
- Role of Nutrition in Epigenetics and Recent Advances of In Silico Studies
- The Road Ahead of the Epi-Informatics Field
Dr. José Medina-Franco received a Bachelor of Science degree in chemistry from the National Autonomous University of Mexico (UNAM) in 1998. That same year, he joined Procter & Gamble in Mexico City, working in the research and development department. He received a Master of Science degree in 2002 and a Ph.D. degree in 2005, both from the UNAM. In 2005, he joined the University of Arizona as a postdoctoral fellow. Dr. Medina-Franco was named Assistant Member at the Torrey Pines Institute for Molecular Studies in Florida in August 2007. Since then, he has conducted research and academic activities at the Institute of Chemistry, UNAM and Mayo Clinic in Scottsdale. In 2014, he was named Full Time Research Professor of the Pharmacy Department, UNAM where he leads a computational group focused on the discovery and development of epi-drugs. He also serves as an Adjunct Professor at the Florida Atlantic University. Dr. Medina-Franco has more than 8 years of experience working on molecular modeling of DNMT inhibitors. He has lead one of the first research groups applying computational tools for drug discovery of epi-hits. His research group has published several research papers, reviews and book chapters focused on the development of DNMT inhibitors using computational methods. One of the major contributions of his group has been the identification of a distinct DNMT inhibitor with a novel molecular scaffold. The hit compound has been used as a starting point for optimization programs and has served as reference for virtual screening campaigns. Dr. Medina-Franco's group has also initiated a novel computer-guided drug repurposing project.